|
RBM7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.64730000049718E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.69240000000137E-05 |
| Normal-vs-Stage2 |
1.84550000004169E-06 |
| Normal-vs-Stage3 |
1.70780999999565E-05 |
| Normal-vs-Stage4 |
3.43010000003474E-06 |
| Stage1-vs-Stage2 |
4.442300E-02 |
| Stage1-vs-Stage3 |
3.528400E-01 |
| Stage1-vs-Stage4 |
1.381800E-01 |
| Stage2-vs-Stage3 |
2.189000E-01 |
| Stage2-vs-Stage4 |
6.241600E-01 |
| Stage3-vs-Stage4 |
4.675200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.14089999999167E-05 |
| Normal-vs-AfricanAmerican |
1.051790E-02 |
| Normal-vs-Asian |
6.788800E-04 |
| Caucasian-vs-AfricanAmerican |
7.699400E-01 |
| Caucasian-vs-Asian |
9.533000E-01 |
| AfricanAmerican-vs-Asian |
7.510000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.40140000048916E-07 |
| Normal-vs-Female |
1.76952999999536E-05 |
| Male-vs-Female |
3.726100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.042660E-03 |
| Normal-vs-Age(41-60Yrs) |
5.10410000043038E-07 |
| Normal-vs-Age(61-80Yrs) |
9.80250000059968E-08 |
| Normal-vs-Age(81-100Yrs) |
4.113600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.850200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.396300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.413800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.523580E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.632000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.880400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.483400E-01 |
| Classical-VS-Follicular |
6.74029999592207E-08 |
| Classical-VS-Other |
1.921960E-01 |
| Classical-VS-Normal |
3.774800E-04 |
| Tall-VS-Follicular |
6.138600E-03 |
| Tall-VS-Other |
2.807400E-01 |
| Tall-VS-Normal |
4.218700E-03 |
| Follicular-VS-Other |
6.470000E-01 |
| Follicular-VS-Normal |
1.16449960785303E-10 |
| Other-VS-Normal |
9.502200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.40630000264619E-08 |
| Normal-vs-N1 |
1.71602999999854E-05 |
| N0-vs-N1 |
6.898400E-01 |
|
|
